Publications by authors named "Ritsuko Yamane"
We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted in Japan to assess the safety of fluoroquinolone antibiotics during pregnancy, focusing on major congenital anomalies in babies born to mothers who used these drugs in their first trimester.
- The study included 411 women exposed to fluoroquinolones and compared them with 1416 women using β-lactams and 1482 women using nonteratogenic medications.
- Results showed the incidence of major congenital anomalies was similar across all groups (1.5% for fluoroquinolones, 2.0% for β-lactams, 1.6% for nonteratogenic drugs), indicating that fluoroquinolone exposure does not significantly increase the risk of congenital anomalies.
To assess the risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol during pregnancy, we conducted a prospective cohort study using counseling data for drug use during pregnancy provided by the Japan Drug Information Institute in Pregnancy and Toranomon Hospital. Counseling information, including drug usage and participants' demographic information, was collected between April 1988 and December 2017. Pregnancy outcome data, including major birth defects, were obtained using a questionnaire administered 1 month after delivery.
View Article and Find Full Text PDFFor leukotriene receptor antagonists (LTRAs), especially pranlukast, safety data during pregnancy is limited. Therefore, we conducted a prospective, two-centered cohort study using data from teratogen information services in Japan to clarify the effects of LTRA exposure during pregnancy on maternal and fetal outcomes. Pregnant women who being counseled on drug use during pregnancy at two facilities were enrolled.
View Article and Find Full Text PDFAim: To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
Methods: Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy.